356 related articles for article (PubMed ID: 12414345)
1. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
[TBL] [Abstract][Full Text] [Related]
2. Combined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt's lymphoma for minimal residual disease analysis.
Busch K; Borkhardt A; Wössmann W; Reiter A; Harbott J
Haematologica; 2004 Jul; 89(7):818-25. PubMed ID: 15257933
[TBL] [Abstract][Full Text] [Related]
3. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
[TBL] [Abstract][Full Text] [Related]
4. Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers.
Welterlin V; Debecker A; Tschieb D; Zanetti C; Lange W; Hénon PR
J Hematother Stem Cell Res; 2000 Dec; 9(6):983-91. PubMed ID: 11177613
[TBL] [Abstract][Full Text] [Related]
5. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
Martínez-Sánchez P; Montejano L; Sarasquete ME; García-Sanz R; Fernández-Redondo E; Ayala R; Montalbán MA; Martínez R; García Laraña J; Alegre A; Hernández B; Lahuerta JJ; Martínez-López J
Br J Haematol; 2008 Sep; 142(5):766-74. PubMed ID: 18637804
[TBL] [Abstract][Full Text] [Related]
7. Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method.
Miglino M; Grasso R; Pietrasanta D; Palmisano GL; Berisso G; Clavio M; Pierri I; Santini G; Canepa L; Gobbi M
J Exp Clin Cancer Res; 2001 Mar; 20(1):95-101. PubMed ID: 11370837
[TBL] [Abstract][Full Text] [Related]
8. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli R; Bandini G; Testoni N; Amabile M; Ottaviani E; Buonamici S; Soverini S; Montefusco V; de Vivo A; Bonifazi F; Tura S; Cavo M
Haematologica; 2000 Sep; 85(9):930-4. PubMed ID: 10980631
[TBL] [Abstract][Full Text] [Related]
9. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
Nakao M; Janssen JW; Flohr T; Bartram CR
Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
[TBL] [Abstract][Full Text] [Related]
11. Detection of bcl-2/IgH rearrangements by quantitative-competitive PCR and capillary electrophoresis.
Telatar M; Grody WW; Emmanouilides C
Mol Diagn; 2001 Sep; 6(3):161-8. PubMed ID: 11571709
[TBL] [Abstract][Full Text] [Related]
12. Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes.
Botsonis T; Tsangaris GT; Mikraki V; Tzortzatou-Stathopoulou F
Anticancer Res; 1999; 19(3B):2211-20. PubMed ID: 10472333
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells.
Martinelli G; Terragna C; Lemoli RM; Cavo M; Benni M; Motta MR; Amabile M; Ottaviani E; Testoni N; de Vivo A; Tura S
Haematologica; 1999 May; 84(5):397-404. PubMed ID: 10329917
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
[TBL] [Abstract][Full Text] [Related]
16. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
[TBL] [Abstract][Full Text] [Related]
17. Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR.
González D; González M; Alonso ME; López-Pérez R; Balanzategui A; Chillón MC; Silva M; García-Sanz R; San Miguel JF
Leukemia; 2003 Jun; 17(6):1051-7. PubMed ID: 12764368
[TBL] [Abstract][Full Text] [Related]
18. Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma.
García-Sanz R; López-Pérez R; Langerak AW; González D; Chillón MC; Balanzategui A; Mateos MV; Alaejos I; González M; Van Dongen JJ; San Miguel JF
Haematologica; 1999 Apr; 84(4):328-35. PubMed ID: 10190947
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal residual disease using clonospecific primers for CDRIII in patients with acute B lymphocytic leukemia with or without Philadelphia chromosome: possibility of clinical application as a tool for improving prognosis.
Maeda Y; Horiuchi F; Morita S; Matsuda M; Shirakawa C; Masaki H; Koyama A; Hamazaki H; Fujimoto T; Irimajiri K
Exp Hematol; 1994 Aug; 22(9):881-7. PubMed ID: 8062887
[TBL] [Abstract][Full Text] [Related]
20. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
